Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment
暂无分享,去创建一个
Stefan J. Teipel | Ping He | Anders Wallin | Harald Hampel | Michael Ewers | Kaj Blennow | Yong Shen | K. Blennow | H. Hampel | M. Ewers | S. Teipel | A. Wallin | Yong Shen | P. He | K. Bürger | Zhenyu Zhong | Katharina Bürger | Zhenyu Zhong | C. McAllister | Carrie E. McAllister
[1] P. Greengard,et al. The Transmembrane Domain of the Alzheimer's β-Secretase (BACE1) Determines Its Late Golgi Localization and Access to β-Amyloid Precursor Protein (APP) Substrate* , 2001, The Journal of Biological Chemistry.
[2] K. Blennow,et al. Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[3] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[4] T. Klockgether,et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[5] K. Blennow,et al. CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.
[6] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[7] A. Farmer,et al. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. , 1988, Archives of general psychiatry.
[8] F. Kametani,et al. Extracellular release of BACE1 holoproteins from human neuronal cells. , 2005, Biochemical and biophysical research communications.
[9] H. Arai,et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.
[10] K. Blennow,et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study , 2005, Neurology.
[11] Katharina Buerger,et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.
[12] J. Tang,et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] David G. Tew,et al. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.
[14] H. Soininen,et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[15] F. Bouwman,et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. , 2006, Clinical chemistry.
[16] G. Stefano,et al. Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. , 2005, Medical science monitor : international medical journal of experimental and clinical research.
[17] E. Bigler,et al. Dementia, quantitative neuroimaging, and apolipoprotein E genotype. , 2000, AJNR. American journal of neuroradiology.
[18] V. Katta,et al. Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties. , 2000 .
[19] R. Doms,et al. Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme , 2000, The Journal of Biological Chemistry.
[20] G. Multhaup,et al. Maturation and Pro-peptide Cleavage of β-Secretase* , 2000, The Journal of Biological Chemistry.
[21] J. Cummings,et al. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.
[22] J. Morris,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.
[23] R. Petersen,et al. Mild cognitive impairment , 2006, The Lancet.
[24] I. Alafuzoff,et al. Glycosylation changes in Alzheimer’s disease as revealed by a proteomic approach , 2004, Neuroscience Letters.
[25] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[26] J. Morris,et al. Current concepts in mild cognitive impairment. , 2001, Archives of neurology.
[27] H. Cai,et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .
[28] M. Citron,et al. Expression Analysis of BACE2 in Brain and Peripheral Tissues* , 2000, The Journal of Biological Chemistry.
[29] J. Zhang,et al. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.
[30] H. Möller,et al. Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.
[31] J. H. Boo,et al. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. , 2003, Biochemical and biophysical research communications.
[32] F. Acquati,et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region , 2000, FEBS letters.
[33] J. Trill,et al. Characterization of the Glycosylation Profiles of Alzheimer's β-Secretase Protein Asp-2 Expressed in a Variety of Cell Lines* , 2001, The Journal of Biological Chemistry.
[34] B. Reisberg,et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease , 2004, Journal of internal medicine.
[35] G. Perry,et al. β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways , 2005, Journal of neurochemistry.
[36] H. Qing,et al. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] A. Elbein,et al. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. , 1987, Annual review of biochemistry.
[38] C. Masters,et al. CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias , 2006, Neurology.
[39] G. Perry,et al. Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons , 2002, Neurobiology of Disease.
[40] M. Wittekind,et al. Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. , 2003, Archives of biochemistry and biophysics.
[41] Erin D Bigler,et al. Temporal lobe morphology in normal aging and traumatic brain injury. , 2002, AJNR. American journal of neuroradiology.
[42] K. Blennow,et al. Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients , 2003, Experimental Neurology.
[43] N. Ostermann,et al. Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. , 2006, Journal of molecular biology.
[44] H. Qing,et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] N. Bresolin,et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. , 2006, Archives of neurology.
[46] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[47] P. Wong,et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.